National Healthcare Spending in the U.S. Was Nearly $5 Trillion (with a “T”) in 2023 – New...
Health Populi December 18, 2024
Startup SiteOne Secures $100M to Forge Ahead With Novel Non-Opioid Pain Meds
MedCity News December 18, 2024
SiteOne Therapeutics develops drugs that target sodium channels, the “wiring” in the body that transmits pain signals. Because SiteOne’s targets are located in the peripheral nervous system, they should not pose the same addiction risks as opioids, which hit receptors in the central nervous system.
Addiction risks from opioid drugs come from their targeting of receptors found primarily in the central nervous system. Other pathways are associated with pain, but many research efforts to hit them have fallen short of yielding viable drugs. SiteOne Therapeutics is one of a growing number of companies trying to treat pain with novel non-opioid approaches. With a lead program on track toward a proof-of-concept Phase 2 test next year, the startup on Wednesday announced...
Today's Sponsors
Today's Sponsor